BrainStorm Cell Therapeutics (BCLI) Flash Note 30092024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BCLI on Friday confirmed its reverse stock split (R/S) to become effective today 30 Sept 2024 (to maintain Nasdaq listing). Reverse stock splits are often (though not always) an effective mechanism and often lead to an upwards re-rating as psychological market factors come into play. There is also a usual market clearing mechanism that often leads to net selling in the early days. BCLI has also announced 24 Sept, the acceptance of two extracts featuring NurOwn® and subject to a successful reverse split we would expect a number of positive new announcements with respect to the PIIIb trial rollout.Brainstorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; and Parkinson's disease. NurOwn? technology is based on manufacturing protocol, which induces the differentiation of purified and expanded bone marrow-derived mesenchymal stem cells and consistently generates cells that release multiple neurotrophic factors to modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.
ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.
We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.
Our independent research is designed to educate our professional investor readers with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.
We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.
Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.